The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2007Functional Inhibition of RasGRF1 in the MPTP-lesioned NHP Model for Treating Levodopa-induced Dyskinesia
Objective/Rationale:
Levodopa-induced dyskinesias are caused by an increased and aberrant response of dopamine receptors to dopamine in the striatum. Among other intracellular pathways, the MAP kinase... -
Target Validation, 2007Validation of metabotropic glutamate-receptor type 5 as a target for the treatment of L-DOPA-induced dyskinesia in a macaque model of Parkinson´s disease
Objective/Rationale:
Metabotropic glutamate receptor type 5 (mGluR5) is abundantly expressed in striatal neurons, where it modulates the response to glutamatergic and dopaminergic inputs. Previous... -
Target Validation, 2007Inhibition of c-Abl Tyrosine Kinase as a Novel Therapy to Prevent PD ProgressionObjective/Rationale: Mutations in the parkin gene cause early-onset autosomal recessive PD. We have discovered that parkin is modified by an oxidative-stress induced signaling kinase, c...
-
Rapid Response Innovation Awards, 2007Unraveling the genetic basis for alpha-synuclein oligomerization in living cells using bimolecular fluorescence complementation
Oligomerization of alpha-synuclein is hypothesized to be the pathogenic mechanism of protein aggregate formation and cell death in neurons of PD patients. Dr. Outeiro proposes to develop an assay to...
-
Target Validation, 2007Validation of Sirtuin 2 Deacetylase as a Therapeutic Target in Parkinson’s disease
Objective/Rationale:
A major known risk factor in Parkinson’s disease is the misfolding, aggregation and abnormal accumulation of the protein alpha-synuclein. The goal of the proposed work is to... -
Rapid Response Innovation Awards, 2007Understanding the Role of Glucocerebrosidase in Parkinson's Disease Pathogenesis: Toward a New Genetic Model of Sporadic PD
Gaucher’s disease is a glycosphingolipid-storage disease in which homozygous mutations are found in the lysosomal enzyme glucocerebrosidase (GBA) gene. PD and Gaucher’s disease share many clinical and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.